The expanding realm of prion phenomena in neurodegenerative disease
- PMID: 19448400
- PMCID: PMC2712602
- DOI: 10.4161/pri.3.2.8754
The expanding realm of prion phenomena in neurodegenerative disease
Abstract
The aggregation of a soluble protein into insoluble, beta-sheet rich amyloid fibrils is a defining characteristic of many neurodegenerative diseases, including prion disorders. The prion protein has so far been considered unique because of its infectious nature. Recent investigations, however, suggest that other amyloid-forming proteins associated with much more common diseases, such as tau, alpha-synuclein, amyloid beta and polyglutamine proteins, while not infectious in the classical sense, share certain essential properties with prions that may explain phenotypic diversity, and patterns of spread within the nervous system. We suggest a common mechanism of pathogenesis of myriad sporadic and inherited neurodegenerative diseases based on templated conformational change.
Similar articles
-
Prion-like mechanisms in neurodegenerative diseases.Nat Rev Neurosci. 2010 Mar;11(3):155-9. doi: 10.1038/nrn2786. Epub 2009 Dec 23. Nat Rev Neurosci. 2010. PMID: 20029438 Free PMC article. Review.
-
Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases?Biomolecules. 2021 Feb 2;11(2):207. doi: 10.3390/biom11020207. Biomolecules. 2021. PMID: 33540845 Free PMC article. Review.
-
Expanding spectrum of prion diseases.Emerg Top Life Sci. 2020 Sep 8;4(2):155-167. doi: 10.1042/ETLS20200037. Emerg Top Life Sci. 2020. PMID: 32803268 Review.
-
What is strain in neurodegenerative diseases?Cell Mol Life Sci. 2020 Feb;77(4):665-676. doi: 10.1007/s00018-019-03298-9. Epub 2019 Sep 17. Cell Mol Life Sci. 2020. PMID: 31531680 Free PMC article. Review.
-
Neurodegeneration. Could they all be prion diseases?Science. 2009 Dec 4;326(5958):1337-9. doi: 10.1126/science.326.5958.1337. Science. 2009. PMID: 19965731 No abstract available.
Cited by
-
Context dependence of protein misfolding and structural strains in neurodegenerative diseases.Biopolymers. 2013 Nov;100(6):722-30. doi: 10.1002/bip.22283. Biopolymers. 2013. PMID: 23893572 Free PMC article.
-
The toll-like receptor agonist imiquimod is active against prions.PLoS One. 2013 Aug 16;8(8):e72112. doi: 10.1371/journal.pone.0072112. eCollection 2013. PLoS One. 2013. PMID: 23977222 Free PMC article.
-
Natural compounds may open new routes to treatment of amyloid diseases.Neurotherapeutics. 2013 Jul;10(3):429-39. doi: 10.1007/s13311-013-0192-7. Neurotherapeutics. 2013. PMID: 23670234 Free PMC article. Review.
-
Longitudinal Assessment of Tau-Associated Pathology by 18F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study.Diagnostics (Basel). 2021 Oct 12;11(10):1874. doi: 10.3390/diagnostics11101874. Diagnostics (Basel). 2021. PMID: 34679572 Free PMC article.
-
An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Hum Mol Genet. 2012 Feb 1;21(3):664-80. doi: 10.1093/hmg/ddr500. Epub 2011 Nov 3. Hum Mol Genet. 2012. PMID: 22052286 Free PMC article.
References
-
- Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B. Cell-free formation of protease-resistant prion protein. Nature. 1994;370:471–474. - PubMed
-
- Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med. 1998;4:1157–1165. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical